1	An integrated polygenic score stratifies risk of peripheral artery disease and adverse
2	limb events in ancestrally diverse cohorts
3	Short title: Integrated polygenic risk prediction for PAD
4	
5	Alyssa M. Flores, MD ^{a-c*} ; Yunfeng Ruan, PhD ^{b,c*} ; Anika Misra, BS ^{b,c} ; Margaret S.
6	Selvaraj, PhD ^{b,c} ; Tiffany R. Bellomo, MD ^{a-c} ; Tetsushi Nakao, MD, PhD ^{b,c} ; Kenneth
7	Rosenfield, MD ^{d,e} ; Matthew Eagleton, MD ^{a,e} ; Whitney Hornsby, PhD ^{b,c} ; Aniruddh P.
8	Patel, MD ^{b-e#} ; Pradeep Natarajan, MD, MSc ^{b-e#}
9	
10	^a Division of Vascular and Endovascular Surgery, Department of Surgery,
11	Massachusetts General Hospital, Boston, USA. ^b Cardiovascular Disease Initiative,
12	Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Center for
13	Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston,
14	Massachusetts, USA. dHarvard Medical School, Boston, Massachusetts, USA. Division
15	of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston,
16	Massachusetts, USA.
17	*These authors equally contributed to the work. #These authors jointly supervised the
18	work.
19	
20	Address for Correspondence:
21	Aniruddh P. Patel, MD and Pradeep Natarajan, MD, MSc
22	185 Cambridge Street, CPZN 3.184
23	Boston, MA 02114

1	Phone: 617-643-3451 Fax: 617-726-2203
2	Email: apatel32@mgh.harvard.edu Twitter: @AniruddhPatelMD
3	Email: pnatarajan@mgh.harvard.edu Twitter: @pnatarajanmd
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

1 Abbreviations

- 2 All of Us, AoU.
- 3 Ankle-brachial index, ABI.
- 4 Body mass index, BMI.
- 5 Coronary artery disease, CAD.
- 6 Current Procedural Terminology, CPT.
- 7 Diastolic blood pressure, DBP.
- 8 Electronic health record, EHR.
- 9 Genome-wide association study, GWAS.
- 10 Glomerular filtration rate, GFR.
- 11 High-density lipoprotein cholesterol, HDL-C.
- 12 International Classification of Disease, ICD.
- 13 Least Absolute Shrinkage and Selection Operator, LASSO.
- 14 Low-density lipoprotein cholesterol, LDL-C.
- 15 Major adverse limb events, MALE.
- 16 Mass General Brigham Biobank, MGBB.
- 17 Office of Population Censuses and Surveys, OPCS.
- 18 Peripheral artery disease, PAD.
- 19 Polygenic risk scores, PRS.
- 20 Principal components, PCs.
- 21 Research Patient Data Registry, RPDR.
- 22 Systolic blood pressure, SBP.
- 23 United States Preventive Services Task Force, USPSTF.

1 Abstract

2	Background and Aims: Peripheral artery disease (PAD) is a heritable atherosclerotic
3	condition that is underdiagnosed and undertreated. With growing knowledge of the
4	genetic basis for PAD and related risk factors, this study sought to construct a new
5	polygenic score for PAD (GPS _{PAD}).
6	
7	Methods: GPSPAD was constructed by integrating multi-ancestry summary statistics for
8	PAD and related traits. GPS_{PAD} was trained in a UK Biobank dataset of 96,239
9	individuals and validated in a holdout UK Biobank dataset (N=304,294) and All of Us
10	(AoU; N=237,173) and Mass General Brigham Biobank (MGBB, N=37,017).
11	
12	Results: GPS_{PAD} was associated with an OR-per SD increase of 1.64 in the UK Biobank
13	dataset (95% CI 1.60-1.68). Compared to previously published PAD polygenic scores,
14	GPS _{PAD} was more strongly associated with PAD in AoU and MGBB, including enhanced
15	transferability to non-European subgroups. GPSPAD improved discrimination of incident
16	PAD (Δ C-statistic 0.030) that was nearly equivalent to the additive performances of
17	diabetes (Δ C-statistic 0.029) and smoking (Δ C-statistic 0.034). GPS _{PAD} was associated
18	with reduced ankle-brachial index in the MGBB with the top 8% of individuals having a
19	mean ABI \leq 0.90 when assessed. Among individuals with prevalent PAD, GPS _{PAD}
20	consistently identified individuals at high MALE-risk in the UK Biobank (HR 1.48; 95%
21	CI 1.24-1.77), MGBB, (HR 1.34; 95% CI 1.12-1.60), and AoU (HR 1.33; 95% CI 1.12-
22	1.58).

23

1	Conclusions: An integrated, multi-ancestry polygenic score for PAD predicts disease
2	and adverse limb outcomes in three diverse cohorts. Incorporating polygenic risk into
3	PAD care has the potential to guide screening and tailor management to prevent MALE.
4	
5	Key Words
6	Peripheral artery disease, polygenic risk, precision medicine
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

1 Introduction

2 Peripheral artery disease (PAD) is an atherosclerotic vascular condition that affects a global population of 230 million adults with high resource utilization owing to 3 4 both systemic and limb ischemic events.^{1,2} While PAD shares risk factors with coronary artery disease (CAD), 32-54% of individuals presenting with PAD do not have clinically 5 significant coronary or cerebrovascular disease.^{3,4} In addition, there are differences in 6 7 the major etiologies of acute events in CAD and PAD. Ischemic CAD events most 8 commonly result from plaque rupture, whereas the cause of acute limb ischemia is most 9 commonly owing to embolism or *in situ* thrombosis, regardless of atherosclerosis 10 extent.⁵ Indeed, the increasingly recognized role of thrombosis in PAD is also supported 11 by the discovery of genetic variants in coagulation factors, including mutations in Factor 12 V Leiden, which have been uniquely associated with PAD and not CAD.⁶ 13 Clinical subsets of PAD include asymptomatic, claudication, and chronic-limb 14 threatening ischemia (CLTI) resulting in tissue loss and major adverse limb events 15 (MALE). MALE are a devastating complication and are often associated with critical 16 illness, numerous resource-intensive attempts at revascularization, and prolonged 17 hospital stays as part of the limb salvage effort. Despite its high morbidity, PAD is grossly underdiagnosed and has a lack of consensus on screening indications. For 18 19 example, while European and American guidelines recommend consideration of 20 screening based on age and risk factors, the United States Preventive Services Task 21 Force (USPSTF) does not recommend screening regardless of risk factors.⁷⁻⁹ 22 Conflicting recommendations have implications on care implementation, for example, in 23 the U.S. where preventive service coverage is guided by USPSTF recommendations.¹⁰

1	In addition, there is no standard tool to predict complications before advanced disease
2	develops. Such a tool would be useful as there are contemporary antithrombotic
3	treatments targeted to prevent MALE but remain underutilized in PAD management. ¹¹
4	Polygenic risk scores (PRS) provide a quantitative metric for the inherited
5	component of disease risk by integrating common genetic variants discovered from
6	genome-wide association studies (GWAS) into a single instrument. As PAD has an
7	estimated heritability of 20-50% ^{12,13} , incorporation of genetic factors offers an
8	opportunity to optimize risk stratification. While there have been advances in PRS for
9	CAD, there has been limited progress thus far in developments for PAD owing to largely
10	European-based data, lack of validation in external datasets, and unclear transferability
11	across diverse ancestry groups.14-16 Additionally, PRS utility for incident prediction of
12	adverse PAD events has not been described.
13	To address these needs, in the present study, we develop a new genome-wide
14	polygenic score for PAD (GPS $_{PAD}$) that incorporates multi-ancestry GWAS data for PAD
15	and related traits from over 2 million individuals (Figure 1). We assess the performance
16	of GPS _{PAD} in predicting PAD among individuals of diverse ancestry in a 304,294 internal
17	validation cohort and two independent study populations comprising 259,627
18	individuals. Lastly, we apply GPS_{PAD} to predict MALE and identify individuals with
19	clinically important increased risk.
20	
21	Methods

22 Study populations

1	GPS_{PAD} was developed using data from the UK Biobank, a longitudinal cohort study of
2	approximately 500,000 individuals from the United Kingdom aged 40-69 years. ¹⁷
3	Participants were followed for outcomes based on International Classification of
4	Disease 9 th and 10 th revisions (ICD-9/ICD-10) and Office of Population Censuses and
5	Surveys versions 3 and 4 (OPCS-3/OPCS-4). Ancestry was based on self-identified
6	ethnicity and country of origin with African, East Asian, European, Latino, Middle
7	Eastern/North African (MENA), and South Asian categories (Supplemental Tables 1-2).
8	Coding of comorbidities and lifestyle factors is detailed in the Supplemental Materials
9	(Supplemental Table 3).
10	
11	GPS _{PAD} performance was evaluated in two external datasets: Mass General Brigham
12	Biobank (MGBB) and All of Us (AoU). The MGBB is a New England-healthcare based
13	cohort that includes >145,000 patients treated at seven regional hospitals and clinics,
14	including ~56,000 have been genotyped. ¹⁸ Baseline phenotypes are linked to the
15	electronic health record (EHR) with available data from clinical notes, ICD-9/ICD-10,
16	and Current Procedural Terminology (CPT) codes.
17	
18	The AoU Research program is a United States-based cohort study that aims to recruit
19	individuals who have been historically underrepresented in biomedical research. ¹⁹ The
20	program has recruited ~400,000 individuals and includes health questionnaires,
21	biospecimen collection, and longitudinal EHR data.

22

23 Genetic data and quality control

In the UK Biobank, individuals were genotyped using UK BiLEVE Axiom Array or UK
Biobank Axiom Array and centrally imputed to the 1000 Genomes (1000G) Panel,
Haplotype Reference Consortium, or UK10K Panel.^{17,20} After performing quality control
(Details Methods) and excluding individuals of Latino ancestry due to low population
representation (N=11 PAD cases) and unreported/mixed ethnicity, 304,294 individuals
were included for internal validation.

7

MGBB samples were genotyped on Illumina Multi-Ethnic Genotyping Array or Global 8 Screening Array.²¹ Imputation was performed to the multi-ancestry TOPMED r2 9 10 reference panel. Given lack of detailed self-reported ethnicity or ancestry data, ancestry 11 was genetically predicted using a K-nearest neighbor model trained with principal 12 components (PCs) from the 1000G reference panels for European, African, Latino/Ad Mixed American, East Asian, and South Asian (Detailed Methods).¹⁸ We excluded 13 individuals who were in prior discovery GWAS for CAD²² and did not map to a single 14 15 genetic ancestry, leaving 37,017 individuals for external validation.

16

AoU participants were genotyped using the Illumina Global Diversity Array at AoU
genome centers.²³ Similar to the MGBB, there was a lack of detailed reported ancestry
data, thus ancestry was assigned based on genetic similarity. AoU assigns categorical
ancestries to African, Latino/Ad Mixed American, East Asian, South Asian, European,
MENA, and Other based on a random forest classifier trained using gnomAD, Human
Genome Diversity Project, and 1000G reference labels (Detailed Methods).²³ After
exclusion of individuals with missing/other ancestry, 237,173 individuals were included.

1

2 <u>Clinical endpoints</u>

- 3 In the UK Biobank, PAD was defined based on self-reported history, ICD codes, OPCS
- 4 codes for lower extremity revascularization or major amputation, and cilostazol
- 5 prescription (Supplemental Table 4). In AoU, PAD was defined on self-report,
- 6 occurrences of \geq 2 ICD codes, or a single procedure code for revascularization, major
- 7 amputation or supervised exercise therapy for PAD (Supplemental Table 5).²⁴
- 8
- 9 In the MGBB, PAD was derived from phenotypes developed by the Mass General

10 Brigham Research Patient Data Registry (RPDR) based on structured and unstructured

11 clinical data from the EHR (Detailed Methods).²⁵ ABI were extracted from imaging

12 reports retrieved from the RPDR. We selected each individual's minimum ABI and

13 excluded values that were >1.4 or non-compressible.

14

MALE was defined as a surrogate of major amputation and acute limb ischemia based
on diagnosis and procedure codes (Supplemental Tables 6-8). Revascularization
included thrombectomy, thrombolysis, and emergency lower extremity bypass. In the
MGBB, CPT codes for catheter-directed thrombolysis/thrombectomy required
concomitant coding for aortogram or lower extremity angiography to ensure arterial
intervention.

21

22 <u>GPS_{PAD} construction</u>

1 PRS predictive performance is improved by the incorporation of data from increasingly 2 diverse genetic ancestries and consideration of genetically correlated traits.²⁶⁻²⁸ To 3 leverage the common mechanistic pathways of PAD, other atherosclerotic conditions, 4 and PAD risk factors, GWAS results of PAD and 14 candidate traits were considered in 5 GPS_{PAD} construction: PAD, CAD, ischemic stroke, glomerular filtration rate, diabetes 6 mellitus, smoking, systolic blood pressure (SBP), diastolic blood pressure (DBP), low-7 density lipoprotein cholesterol (LDL-C), total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, BMI, carotid plague burden, and carotid intima-media 8 9 thickness (Supplemental Table 9). After collection of GWAS summary statistics, GPSPAD 10 was trained using target data from 96,239 European individuals in the UK Biobank. 11 GWAS results from the UK Biobank were not used to construct GPS_{PAD} such that data 12 for score development and training were non-overlapping.

13

GPS_{PAD} was developed in a two-layer process (**Figure 1**).²⁶ Layer 1 involved using 14 15 ancestry-stratified GWAS data for each trait to calculate multi-ancestry polygenic scores 16 that were optimized according to their PAD predictive performance. Separate scores 17 were constructed using LDpred2, a widely used method that adjusts marginal single nucleotide polymorphism effect sizes for linkage disequilibrium (LD) patterns and 18 selects a subset of variants with non-zero effects to calculate the polygenic score.²⁹ 19 20 Using LDpred2-auto, scores were calculated using GWAS results stratified by African, 21 East Asian, European, Latino, and South Asian ancestry (R bigsnpr v.11.4). This 22 resulted in 100 scores across all ancestries and traits. For each trait, the ancestry-23 specific scores were combined into the best-performing multi-ancestry score per trait

1	using Least Absolute Shrinkage and Selection Operator (LASSO) regression in models
2	predicting PAD (R glmnet v4.0-2). Feature selection was performed iteratively for all 15
3	traits in layer 1, yielding 15 multi-ancestry trait-specific scores with mixing weights
4	detailed in Supplemental Table 9.
5	
6	Layer 2 involved combining trait-specific scores from layer 1 to derive the integrated,
7	multi-trait GPSPAD. Trait scores from Layer 1 were input into a LASSO regression model
8	predicting PAD to construct the final GPS_{PAD} . The final weight in GPS_{PAD} was derived by
9	calculating the proportional weight from layer 1 in layer 2, normalized to 100%. Of the
10	15 candidate trait scores, 11 traits contributed to GPSPAD with mixing weights in
11	Supplemental Table 10. GPS_{PAD} was then calculated in the validation UK Biobank
12	dataset. See Detailed Methods for details on GPSPAD construction.
13	
14	GPS _{PAD} validation and benchmarking
15	GPS_{PAD} was calculated in the MGBB and AoU for external validation. GPS_{PAD}
16	performance was compared with previously published PRS in the Polygenic Score
17	Catalog ³⁰ and a recently reported multi-ancestry polygenic score for CAD (GPS _{CAD}). ²⁶
18	We previously developed GPS_{CAD} utilizing a similar two-layer framework for CAD as in
19	the present study with slight modifications including stepwise regression for feature
20	selection. ²⁶ From the Polygenic Score Catalog, PRS _{PLR} is a single-trait score for PAD
21	developed using LASSO regression and individual-level European data from the UK
22	Biobank. ¹⁵ PRS _{LDpred2} is another single-trait score for PAD trained using UK Biobank
23	data, but was calculated with LDpred2-auto. ¹⁵

1 We also calculated the lifetime risk of PAD in individuals in the UK Biobank based on

- 2 clinical variables using the Johns Hopkins University PAD risk tool
- 3 (http://ckdpcrisk.org/padrisk, Detailed Methods).³¹
- 4

5 <u>Statistical analysis</u>

6 The unadjusted rate of PAD was calculated across percentiles of GPS_{PAD}. Model

7 calibration was assessed with the Hosmer–Lemeshow test (R ResourceSelection v0.3-

8 6) and by comparing the observed and predicted prevalence across percentiles

9 calculated using a logistic regression model with only GPS_{PAD} as a predictor. We

10 estimated PAD risk in the extremes of the GPS_{PAD} distribution using logistic regression

11 models. We also derived the proportion of the population with a given magnitude of risk

12 by calculating the odds ratio (OR) of varying extremes of GPS_{PAD} percentiles compared

13 to the middle quintile group (40-59%).

14

15 The association of GPS_{PAD} and other scores with all PAD (incident and prevalent cases) 16 were assessed using logistic regression. Performance metrics included OR, area under 17 the receiver operator characteristic curve (AUC, R pROC v1.17.0.1), and phenotypic variance explained (Nagelkerke-R²). Incident event analyses were performed using Cox 18 19 proportional hazards models with metrics including hazard ratio (HR) and C-statistic (R 20 survival v3.5-7). MALE analyses were restricted to individuals with prevalent PAD 21 diagnoses. Time-to-MALE curves were estimated using the Kaplan-Meier method, 22 standardized to mean age and gender (R survminer v0.4.9). Linear regression was 23 used to evaluate the relationship between polygenic scores and minimum ABI.

1

2	Logistic, linear, and Cox models including polygenic scores were adjusted for age, sex,
3	genotyping array, and the first ten PCs. Cox models were used to estimate the 10-year
4	incidence of PAD across lifestyle and genetic risk groups, standardized to the mean of
5	covariates in each group. In the UK Biobank, we performed sensitivity analyses to test
6	the strength of GPS_{PAD} associations with PAD and incident MALE after additionally
7	accounting for clinical variables (current smoking, hypertension, diabetes,
8	hyperlipidemia, and chronic kidney disease); and continuous variables for individuals
9	with available physical and laboratory data (SBP, DBP, hemoglobin A1c, HDL-C,
10	estimated untreated LDL-C ³² , GFR, and anti-hypertensive use).
11	
12	GPS_{PAD} and other continuous variables were scaled to a mean of zero and one
13	standard deviation (SD) such that effect sizes indicate OR- or HR-per SD. Statistical
14	significance was defined as P <0.05 or 95% confidence interval (CI) that excluded the
15	null value. Statistical analyses were performed using R-4.1.0.
16	
17	Results:
18	Given that complex diseases such as PAD share genetic backgrounds with related
19	traits, we leveraged this genetic correlation to more fully capture human genetic
20	architecture and construct GPS_{PAD} . ^{6,33,34} GPS_{PAD} included 603,595 variants across 11
21	traits and 5 ancestries, including PAD, smoking, CAD, ischemic stroke, diabetes, SBP,
22	LDL-C, glomerular filtration rate, BMI, carotid IMT, and total cholesterol. While $\mbox{GPS}_{\mbox{PAD}}$

23 was predominantly derived from European discovery data, the score incorporated

genetic variation discovered in African, East Asian, South Asian, and Latino populations
 (Supplemental Table 10). Of the non-European populations, African GWAS discovery
 data contributed the most to GPS_{PAD}.

4

5 Association of GPS_{PAD} with PAD risk

6 Within the UK Biobank, GPS_{PAD} was associated with a OR 1.77 (95% CI: 1.70-1.86) for PAD in the European training sample (Supplemental Table 12). The effect size was 7 8 mildly attenuated in the multiethnic validation cohort including 304,294 individuals, but 9 remained strongly associated with PAD (OR 1.63; 95% CI 1.60-1.68). The holdout 10 validation cohort included 164,108 females (53.9%) and 286,356 participants of 11 European (94%), 7,680 South Asian (2.5%), 6,939 African (2.3%), 1,761 East Asian 12 (0.6%), and 1,558 (0.51%) MENA ancestry. There was a decrement, yet persistently significant association with adjustment for clinical risk factors (OR 1.35; 95% CI 1.31-13 14 1.39) and in a model adjusted for continuous covariates (OR 1.37; 95% CI: 1.33-1.41). 15 16 We found significant differences in PAD rates across the GPS_{PAD} percentile distribution, 17 ranging from 0.78% in the bottom percentile to 7.91% in the top percentile (Figure 2A, 18 Supplemental Table 13). Predicted PAD prevalence was overall consistent with observed prevalence, excluding the >98% percentile where there was slight risk 19 20 underestimation by GPS_{PAD} alone driven by a sharp increase in the observed PAD 21 prevalence (Supplemental Figure 1). GPS_{PAD} stratified individuals in low and high-risk 22 groups with up to 4.71-fold increased PAD risk in the top 1% of GPS_{PAD} (OR 4.71, 95% 23 CI 4.07-5.42) compared to the middle quintile (**Figure 2B**).

2	Compared to previously published scores, GPSPAD resulted in an improvement in effect
3	estimate, discrimination, and proportion of phenotypic variance explained compared to
4	PRS_{PLR} . In a model adjusted for age, sex, genotyping array, and the first ten PCs of
5	ancestry, GPS _{PAD} had an OR of 1.63, AUC of 0.74, and Nagelkerke-R ² of 0.087, while
6	PRS_{PLR} had an OR of 1.20, AUC 0.71, and Nagelkerke- R^2 of 0.064. $PRS_{LDpred2}$ achieved
7	greater performance in the UK Biobank than GPS_{PAD} with OR 2.46 and nearly
8	equivalent discriminative ability with AUC 0.75, however Nagelkerke-R ² and effect sizes
9	in the extremes of PRS _{LDpred2} percentiles strongly suggested overfitting. For example,
10	$PRS_{LDpred2}$ Nagelkerke- R^2 was 0.17 in the UK Biobank validation cohort and OR for the
11	top 1% PRS _{LDpred2} was 71.9 (95% CI 64.9-79.7).
12	
13	GPS _{PAD} identified individuals with distinct risk compared to an integrated polygenic
14	score for CAD (GPS _{CAD}). ²⁶ In the UK Biobank, GPS _{PAD} was more strongly associated
15	with PAD (OR 1.63; 95% CI 1.60-1.68) than GPS _{CAD} (OR 1.48; 95% CI 1.44-1.52) and
16	identified a greater number of high-risk individuals (Supplemental Table 13). For
17	example, the proportion of the UK Biobank population at 3-fold and 4-fold greater odds
18	for PAD was 5.7% (N=17,345) and 1.90% (N=5,782) when classified by $\mbox{GPS}_{\mbox{PAD}},$
19	respectively. There was a comparatively small fraction of individuals at similar PAD risk
20	according to GPS_{CAD} with only 1.90% (N=5,782) at 3-fold greater risk and 0.20%
21	(N=609) at 4-fold greater risk.
22	

1	We then compared polygenic score performance in ancestral subgroups in the UK
2	Biobank (Figure 2C). Across each ancestral population, GPSPAD predicted disease risk
3	in African, European, East Asian, MENA, and South Asian subgroups with effect
4	estimates of 1.26, 1.66, 1.60, 1.64, and 1.25 respectively. While $PRS_{LDpred2}$ and PRS_{PLR}
5	predicted PAD risk in European individuals, both were not associated with PAD in non-
6	European subgroups (Supplemental Table 14). In clinical subgroups, GPS_{PAD}
7	performance was fairly stable, with OR ranges of 1.33-1.72 depending on demographics
8	and the presence of risk factors (Supplemental Figure 2).
9	
10	Validation of GPS _{PAD} in distinct external cohorts
11	GPS _{PAD} was externally validated in two independent multi-ancestry cohorts and showed
12	improved cross-population predictive performance relative to previously published
13	scores. GPS_{PAD} was significantly associated with an increased risk for PAD (OR 1.26;
14	95% CI 1.18-1.37, Figure 3A) in the MGBB, which included 5.3% African (N=1,945),
15	87% European (N=32,139), and 7.9% Latino individuals (N=2,933). GPS _{PAD} performed
16	similarly in AoU (OR 1.21; 95% CI 1.19-1.23), which embodied 22% African (N=51,691),
17	2.2% East Asian (N=5,268), 50% European (N=119,167), 17% Latino (N=39,576),
18	0.21% MENA (N=509), and 0.97% South Asian individuals (N=2,289). Of note, while
19	$PRS_{LDpred2}$ outperformed GPS_{PAD} in the UK Biobank where it was derived, $PRS_{LDpred2}$
20	was not significantly associated with PAD risk in the MGBB (OR 1.02; 95% CI 0.95-
21	1.08; P =0.06) and was more weakly associated with PAD than GPS _{PAD} in AoU (OR
22	1.10; 95% CI 1.08-1.12). GPS _{PAD} consistently had stronger effect sizes than PRS _{PLR} in
23	each external cohort (Figure 3A).

2	When stratifying by ancestry, GPS_{PAD} demonstrated improved transferability in most
3	subgroups (Supplemental Table 14). Among African (N=51,691), European
4	(N=119,167), Latino (N=39,576), and South Asian (N=2,289) individuals in AoU,
5	GPS_{PAD} was the most strongly predictive of PAD compared to previously published
6	scores (Figure 3B). GPS _{PAD} was also transferable to Europeans in the MGBB with a
7	larger effect size (OR 1.26; 95% CI 1.17-1.34) than PRS _{PLR} (OR 1.09; 95% CI 1.02-
8	1.16) and $PRS_{LDpred2}$, which was not associated with disease risk (OR 1.01; 95% CI
9	0.94-1.08). No polygenic scores were associated with PAD in AoU East Asians, AoU
10	MENA, and non-European subgroups in the MGBB (Supplemental Figure 3).
11	
12	Modeling incident PAD according to polygenic risk and clinical risk factors
13	We then analyzed 301,932 participants of the UK Biobank who were free of PAD at
14	study enrollment. Over a median 12.1 years follow-up (interquartile range (IQR) 10.6-
15	13.5 years), incident PAD was observed in 4,202 individuals (1.39%). Within the UK
16	Biobank, the baseline model of age, sex, and ten PCs of ancestry had a C-statistic of
17	0.731 (Figure 4A). The addition of GPS_{PAD} resulted in improvement in discrimination to
18	0.761, which was greater than the improvement of most risk factors also in isolation,
19	and was approximately equivalent to the additive benefit of diabetes (C-statistic 0.760)
20	and smoking (C-statistic 0.765). The greatest improvement in discrimination was
21	observed with the baseline model, clinical variables, and GPS_{PAD} (C-statistic 0.087).
22	

1	Compared to the individual performance of other scores, GPSPAD resulted in greater
2	benefit in discrimination of incident PAD than PRS_{PLR} (C-statistic 0.735) and the lifetime
3	PAD risk score ³¹ (C-statistic 0.675). PRS _{LDpred2} achieved a larger improvement in C-
4	statistic (C-statistic 0.774) from the baseline model compared to GPS_{PAD} , but the HR
5	was drastically large in the UK Biobank where it was wholly derived, and consistent with
6	overfitting (HR 199; 95% CI 172-231), as observed in cross-sectional analyses.
7	
8	In the baseline model, GPS $_{\text{PAD}}$ HR for incident PAD was 1.66 (95% CI 1.61-1.71) and
9	HR 1.37 (95% CI 1.30-1.46) in a multivariable model adjusted for clinical risk factors.
10	When examining the interaction between GPS_{PAD} and clinical variables, we observed a
11	weak interaction with levels of LDL-C (GPS _{PAD} *LDL-C HR 1.05; 95% CI 1.01-1.08;
12	Pinteraction=0.005) and hemoglobin A1c (GPSPAD*hemoglobin A1c HR 1.02; 95% CI 1.00-
13	1.03; Pinteraction=0.01). Lifestyle factors influenced PAD risk across each stratum of
14	genetic risk (Supplemental Table 15). For the high genetic risk group, the standardized
15	10-year incidence of PAD of 3.17% for smokers and decreased to 1.05% for those who
16	refrained from smoking (Figure 4A). There were similar patterns of an offset of genetic
17	risk by modifiable lifestyle factors according to dietary patterns (Figure 4B).
18	
19	Integration of polygenic risk with clinical guidelines
20	We then assessed whether GPS_{PAD} could identify individuals at equivalent risk for

21 incident disease as the high-risk groups that current guidelines recommend screening

22 for PAD.⁸ We first quantified the 10-year incidence of PAD among subgroups of

23 individuals proposed to be candidates for ABI screening according to the AHA/ACC

1 Guidelines.⁸ Individuals above 65y had a 10-year incidence of 2.28% (95% CI 2.16-2 2.41), individuals who were age 50-64y with one risk factor for atherosclerosis had an 3 incidence of 1.23% (95% CI 1.17-1.30%), individuals <50y with diabetes and 1 4 additional risk factor had an incidence of 2.90% (95% CI 1.62-3.21%), and those with 5 known atherosclerosis in another vascular bed had the greatest incidence of 5.95% 6 (95% CI 5.48-6.42). As a comparison, incidence rates ranged from 2.81-4.40% in the top 1-5% GPS_{PAD} compared to the middle guintile distribution (Supplemental Table 16). 7 8 We also looked at age-based combinations of each individual risk factor and compared 9 event rates to subgroups with the combination of risk factors and high polygenic risk. 10 This analysis revealed that the combination of high GPS_{PAD} with one atherosclerosis 11 risk factor identified more individuals who subsequently developed PAD than many of 12 the subgroups defined by the combination of similar risk factors with age (Figure 5A). 13 For example, 7.96% of individuals in the top 5% GPS_{PAD} and diabetes developed PAD, 14 as compared to a 4.02% incident rate among individuals aged 50-64y with diabetes. 15 Similarly, there was a relative increase in PAD cases among individuals in the top 5% 16 GPS_{PAD} with dyslipidemia (5.63%; 95% CI 4.88-6.36) compared to individuals 50-64y 17 with dyslipidemia (1.97%; 95% CI 1.80-2.15). The addition of the top 5% GPS_{PAD} also increased the proportion of additional cases of PAD when combined with other 18 atherosclerotic conditions such as CAD and carotid stenosis compared to consideration 19 20 of the conditions alone (Supplemental Table 16).

21

22 Predicting ankle-brachial indices based on polygenic risk

1	In addition to predicting binary PAD presence, we evaluated whether GPS_{PAD} was
2	associated with minimum ABI for a subset of individuals in the MGBB (N=883,
3	Supplemental Figure 4). The minimum ABI was first used to validate the PAD
4	phenotype in the MGBB. PAD cases indeed had a lower mean ABI compared to
5	controls (0.78 vs. 1.10; P<2x10 ⁻¹⁶ , Supplemental Figure 5). After adjusting for age, sex,
6	and the first ten PCs, GPS _{PAD} was significantly associated with lower ABI (Figure 5B),
7	while previously published scores were not (all <i>P</i> >0.1, Supplemental Table 17). Each
8	SD increase in GPS _{PAD} was associated with an -0.088 reduction in ABI (95% CI -0.161
9	to -0.015; <i>P</i> =0.019). Based on the percentile distribution in the MGBB, the group in the
10	top 8% GPS _{PAD} had a mean ABI <u><</u> 0.90 diagnostic for PAD (95% CI 0.83-0.97, Figure
11	5C) . ³⁵
10	
12	
12	Association of GPSPAD with incident major adverse limb events
12 13 14	<u>Association of GPS_{PAD} with incident major adverse limb events</u> Lastly, we assessed whether polygenic background could identify individuals at
13 14 15	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD}
12 13 14 15 16	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification
12 13 14 15 16 17	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of
12 13 14 15 16 17 18	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of GPS _{PAD}) in the UK Biobank had a 75% higher relative risk of incident MALE (HR 1.75;
12 13 14 15 16 17 18 19	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of GPS _{PAD}) in the UK Biobank had a 75% higher relative risk of incident MALE (HR 1.75; 95% CI 1.18-2.57; <i>P</i> =0.005) over a median of 12.9 years (IQR 11.7-14.1) compared to
12 13 14 15 16 17 18 19 20	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of GPS _{PAD}) in the UK Biobank had a 75% higher relative risk of incident MALE (HR 1.75; 95% Cl 1.18-2.57; <i>P</i> =0.005) over a median of 12.9 years (IQR 11.7-14.1) compared to the remainder of the PAD population. The top 20% GPS _{PAD} also had an increased risk
12 13 14 15 16 17 18 19 20 21	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of GPS _{PAD}) in the UK Biobank had a 75% higher relative risk of incident MALE (HR 1.75; 95% CI 1.18-2.57; <i>P</i> =0.005) over a median of 12.9 years (IQR 11.7-14.1) compared to the remainder of the PAD population. The top 20% GPS _{PAD} also had an increased risk of MALE in the MGBB (HR 1.56; 95% CI 1.06-2.30; <i>P</i> =0.02) during 5.19 years of follow-
12 13 14 15 16 17 18 19 20 21 22	Association of GPS _{PAD} with incident major adverse limb events Lastly, we assessed whether polygenic background could identify individuals at increased risk for MALE after PAD diagnosis. In external validation cohorts, GPS _{PAD} was significantly associated with incident MALE and provided improved risk stratification than previously published scores. Individuals with high polygenic risk (top 20% of GPS _{PAD}) in the UK Biobank had a 75% higher relative risk of incident MALE (HR 1.75; 95% CI 1.18-2.57; <i>P</i> =0.005) over a median of 12.9 years (IQR 11.7-14.1) compared to the remainder of the PAD population. The top 20% GPS _{PAD} also had an increased risk of MALE in the MGBB (HR 1.56; 95% CI 1.06-2.30; <i>P</i> =0.02) during 5.19 years of follow- up (IQR 2.63-7.75) and AoU cohort (HR 1.51; 95% CI 1.03-2.24; <i>P</i> =0.03) over 2.32

1
1

2	In the overall PAD cohort in the UK Biobank, GPSPAD was significantly associated with
3	MALE (HR 1.48; 95% CI 1.24-1.77; Figure 6B), which was diminished but remained
4	associated after multivariable adjustment (HR 1.30; 95% CI 1.07-1.59; P=0.009).
5	Associations of GPS_{PAD} with incident MALE remained significant in the prevalent PAD
6	cohorts of the MGBB (HR 1.34; 95% CI 1.12-1.60) and AoU (HR 1.33; 95% CI 1.11-
7	1.58; Figure 6B), while other scores demonstrated weaker or non-significant risk
8	estimates.
9	
10	Discussion:
11	Using ancestry-stratified GWAS results from multiple populations, we developed
12	a polygenic score that aggregates the effects of variants in PAD and related traits
13	across five ancestries. GPS_{PAD} shows strong disease prediction and is transferable to
14	external cohorts with ancestrally diverse populations, demonstrating associations with
15	lower ABI and greater effect sizes for PAD association in non-European populations.
16	This new score also identifies more high-risk individuals than a polygenic score for
17	CAD, highlighting the differences in genetic risk for these atherosclerotic conditions. ²⁸
18	Moreover, among individuals with diagnosed PAD, high GPS_{PAD} predicts future risk of
19	MALE, defined as a surrogate of major amputation and acute limb ischemia.
20	Prior polygenic scores for PAD were solely derived from European data or
21	employed GWAS data from a single population and were not validated in external
22	cohorts. ¹⁴⁻¹⁶ Our computational framework considered variants discovered from >2
23	million ancestrally diverse individuals and leveraged the pleiotropy between PAD and

related risk factors to enhance genetic risk prediction.²⁶ Such approaches that
incorporate genome-wide genetic correlation increase the power of polygenic
association analyses and improve prediction accuracy.^{36,37} GPS_{PAD} was indeed the most
strongly predictive of PAD risk in external validation cohorts. Unlike previously published
polygenic scores, GPS_{PAD} was able to predict PAD risk in Latino individuals in All of Us
and both African and South Asian individuals in two distinct cohorts (All of Us and the
UK Biobank).

8 In prospective analysis in the UK Biobank, GPS_{PAD} was associated with incident 9 PAD with similar effect sizes as cross-sectional analysis. The inclusion of GPSPAD 10 resulted in a comparable benefit in discriminative capacity as those afforded by smoking 11 and diabetes.³ We also note a significant interaction between GPS_{PAD} and LDL-C or 12 hemoglobin A1c in models predicting incident PAD. This suggests that individuals with higher GPS_{PAD} may have a greater benefit from dietary changes, statin therapy, or 13 14 glycemic control. Indeed, post-hoc analyses of statin therapy trials demonstrate that 15 statins confer a greater cardiovascular risk reduction in those with high genetic risk compared to the general population.³⁸ 16

Current European guidelines more broadly recommend consideration of screening based on age and cardiovascular risk factors, while American cardiovascular society guidelines recommend screening for PAD with ABI in four groups: age<u>>65</u> years, age 50-64 years with atherosclerotic risk factors, age <50 years with diabetes and 1 risk factor, and history of atherosclerosis in other vascular beds.^{8,9} Addition of the GPS_{PAD} has the potential to further streamline these screening recommendations and identify higher risk populations. When evaluating the combination of polygenic risk and

clinical risk assessment, incorporation of the top 5% polygenic risk with conventional
risk factors identified more individuals who went on to develop PAD compared to the
combination of risk factors with age. These results suggest the top 5% genetic risk and
presence of risk factors could be considered a criteria for screening with ABIs to
establish PAD diagnosis. Indeed, when leveraging ABIs, our analysis revealed an ABI
diagnostic of PAD associated with high GPS_{PAD} in the MGBB, although replication in
other cohorts is needed.

8 Secondary prevention efforts in PAD focus on limb salvage. MALE are 9 associated with poor prognosis for PAD patients and represent index events for 10 subsequent hospitalizations, reinterventions, major adverse cardiac events, and even 11 mortality.³⁹ Once acute limb ischemia occurs, numerous returns to the operating room 12 for revascularization with combined exposure to anticoagulation and thrombolytic 13 therapy and subsequent reperfusion is a major physiologic stress in an already 14 comorbid patient population. Staging systems such as the Wound, Ischemia, and foot 15 Infection are used to determine amputation risk in the CLTI population, but there are no current vetted clinical tools for predicting MALE early in the disease course.³ Our 16 17 analysis found that GPS_{PAD} stratified MALE risk specifically in the PAD population and 18 remained consistently predictive of incident MALE in the UK Biobank, Mass General Brigham Biobank, and All of Us. 19

These findings have several implications. First, an individual's genetic risk in combination with their cardiovascular risk factor profile may be employed as a criteria for consideration of screening with non-invasive vascular testing. PAD is an underdiagnosed and undertreated condition with guideline-directed therapies that lag

that of CAD.⁸ Incorporation of polygenic risk may be used as an adjunct to clinical risk 1 2 assessment to identify a greater proportion of high-risk individuals for medical optimization. In addition, as with studies of polygenic risk and CAD^{38,40-42}, there may be 3 4 early benefits for targeted intensive lifestyle and risk factor optimization in PAD with high 5 genetic risk. However, there is need for further testing the effect of polygenic scores on 6 hard cardiovascular outcomes in prospective studies, particularly among younger age groups. Given that high GPS_{PAD} was strongly associated with MALE in three distinct 7 8 PAD cohorts, there is promise for implementation of polygenic scores into secondary 9 prevention measures for vascular practitioners, such as in frequency of surveillance or 10 guiding more aggressive or prolonged antithrombotic therapies shown to reduce MALE 11 incidence.^{11,39}

12 Our study has several limitations. First, GPS_{PAD} was trained using data from largely European individuals due to limitations in sample size of other ancestries. 13 14 Nevertheless, we demonstrated evidence of portability to non-European groups, not 15 previously achieved by prior PAD polygenic scores. Second, this study was restricted to 16 individuals with genetic similarities to single ancestries and had more limited cases of 17 non-European groups, which could have limited power to detect associations especially 18 among the East Asian and MENA groups. Race alone was importantly not used to infer 19 ancestry, however such broad ancestral categorizations can mask heterogeneity in 20 polygenic score performance in some groups. Tailoring of polygenic scores to non-21 European target data, continued recruitment of underrepresented populations in 22 biobanks, and development of methods to account for admixture should be a priority to 23 improve polygenic score performance. Lastly, PAD and MALE phenotyping were based

on diagnosis and procedures codes from the EHR. There could have been variation in
the quality of definitions between cohorts that influenced analyses towards null
associations. However, we used non-invasive studies in the MGBB as another
surrogate for PAD and observed similar associations of polygenic risk with binary PAD
classifications in both the MGBB and AoU, where the latter is comprised of several U.S.
healthcare institutions.

7

8 Ethics Approval

Individuals in the UK Biobank, All of Us, and Mass General Brigham Biobank underwent
signed consent for genetic sequencing, storage of biological specimens, and access to
electronic health record data. This research was conducted using the UK Biobank
resource under application number 7089. Secondary analyses of the UK Biobank,
MGBB, and AoU was approved by the Massachusetts General Hospital Institutional
Review Board.

15

16 Data Availability

Individual-level data from the UK Biobank and All of Us are available upon request from
researchers to each organization. This study used Controlled Tier data from All of Us
which is available to authorized users on the All of Us Researcher Workbench. GPS_{PAD}
constructed in this paper will be made available in the Polygenic Score Catalog
following publication. Polygenic scores used for comparison of GPSPAD performance
are available in the Polygenic Score Catalog through accession ID PGS001843 and
PGS002055.

1

2 Acknowledgments

3 We thank the participants and investigators in the UK Biobank, All of Us, and Mass

4 General Brigham Biobank for their contributions to this study.

5

6 Funding

7 This work was supported by the Harvard Medical School LaDue Fellowship in

8 Cardiovascular Medicine (to A.M.F.) and National Institutes of Health (grants

9 R01HL127564 and U01HG011719 to P.N. and K08HL168238 to A.P.P.).

10

11 Disclosure of Interest

12 P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / 13 Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life 14 Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Foresite 15 Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, TenSixteen 16 17 Bio, and Tourmaline Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, 18 Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all 19 unrelated to the present work. All other authors have no relevant disclosures.

20

21

22

1 References:

- 2 1. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk
- 3 factors for peripheral artery disease in 2015: an updated systematic review and
- 4 analysis. Lancet Glob Health 2019;7:e1020-e1030. doi: 10.1016/S2214-
- 5 109X(19)30255-4
- 6 2. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in
- 7 patients with peripheral artery disease in the United States. Circ Cardiovasc Qual
- 8 *Outcomes* 2010;**3**:642-651. doi: 10.1161/CIRCOUTCOMES.109.930735
- 9 3. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and
- 10 Polyvascular Disease. *Circ Res* 2021;**128**:1818-1832. doi:
- 11 10.1161/CIRCRESAHA.121.318535
- 12 4. Hackler EL, 3rd, Hamburg NM, White Solaru KT. Racial and Ethnic Disparities in
- 13 Peripheral Artery Disease. Circ Res 2021;**128**:1913-1926. doi:
- 14 10.1161/CIRCRESAHA.121.318243
- 15 5. Narula N, Olin JW, Narula N. Pathologic Disparities Between Peripheral Artery
- 16 Disease and Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2020;40:1982-
- 17 1989. doi: 10.1161/ATVBAHA.119.312864
- 18 6. Klarin D, Lynch J, Aragam K, et al. Genome-wide association study of peripheral
- 19 artery disease in the Million Veteran Program. *Nat Med* 2019;**25**:1274-1279. doi:
- 20 10.1038/s41591-019-0492-5
- 21 7. Mills J, Duffy M. Screening for Peripheral Artery Disease and Cardiovascular
- 22 Disease Risk Assessment with the Ankle-Brachial Index. *Am Fam Physician*
- 23 2018;**98**:754-755. doi:

1	8. Gornik HL, Aronow HD, Goodney PP, et al. 2024
2	ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the
3	Management of Lower Extremity Peripheral Artery Disease: A Report of the American
4	College of Cardiology/American Heart Association Joint Committee on Clinical Practice
5	Guidelines. Circulation 2024; 149 :e1313-e1410. doi: 10.1161/CIR.000000000001251
6	9. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the
7	management of peripheral arterial and aortic diseases. Eur Heart J 2024. doi:
8	10.1093/eurheartj/ehae179
9	10. Internal Revenue Service, Department of the Treasury; Employee Benefits
10	Security Administration, Department of Labor; Centers for Medicare & Medicaid
11	Services, Department of Health and Human Services. Coverage of Certain Preventive
12	Services Under the Affordable Care Act.
13	https://www.federalregister.gov/documents/2015/07/14/2015-17076/coverage-of-
14	certain-preventive-services-under-the-affordable-care-act (December 21, 2023)
15	11. Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of
16	Peripheral Artery Disease. Circ Res 2021; 128 :1868-1884. doi:
17	10.1161/CIRCRESAHA.121.318258
18	12. Carmelli D, Fabsitz RR, Swan GE, et al. Contribution of genetic and
19	environmental influences to ankle-brachial blood pressure index in the NHLBI Twin
20	Study. National Heart, Lung, and Blood Institute. Am J Epidemiol 2000;151:452-458.
21	doi: 10.1093/oxfordjournals.aje.a010230

1	13.	Murabito JM, Guo CY, Fox CS, D'Agostino RB. Heritability of the ankle-brachial			
2	index: the Framingham Offspring study. Am J Epidemiol 2006;164:963-968. doi:				
3	10.1093/aje/kwj295				
4	14.	Wang F, Ghanzouri I, Leeper NJ, Tsao PS, Ross EG. Development of a			
5	polyg	penic risk score to improve detection of peripheral artery disease. Vasc Med			
6	2022	; 27 :219-227. doi: 10.1177/1358863X211067564			
7	15.	Prive F, Aschard H, Carmi S, et al. Portability of 245 polygenic scores when			
8	deriv	ed from the UK Biobank and applied to 9 ancestry groups from the same cohort.			
9	Am J	<i>Hum Genet</i> 2022; 109 :12-23. doi: 10.1016/j.ajhg.2021.11.008			
10	16.	Zhu K, Qian F, Lu Q, et al. Modifiable Lifestyle Factors, Genetic Risk, and			
11	Incide	ent Peripheral Artery Disease Among Individuals With Type 2 Diabetes: A			
12	Prosp	pective Study. Diabetes Care 2024. doi: 10.2337/dc23-1503			
13	17.	Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep			
14	phen	otyping and genomic data. <i>Nature</i> 2018; 562 :203-209. doi: 10.1038/s41586-018-			
15	0579	-Z			
16	18.	Koyama S, Wang Y, Paruchuri K, et al. Decoding Genetics, Ancestry, and			
17	Geospatial Context for Precision Health. medRxiv 2023. doi:				
18	10.11	101/2023.10.24.23297096			
19	19.	All of Us Research Program I, Denny JC, Rutter JL, et al. The "All of Us"			
20	Rese	arch Program. <i>N Engl J Med</i> 2019; 381 :668-676. doi: 10.1056/NEJMsr1809937			
21	20.	Genomes Project C, Auton A, Brooks LD, et al. A global reference for human			
22	gene	tic variation. <i>Nature</i> 2015; 526 :68-74. doi: 10.1038/nature15393			

- 1 21. Boutin NT, Schecter SB, Perez EF, et al. The Evolution of a Large Biobank at
- 2 Mass General Brigham. *J Pers Med* 2022;**12**. doi: 10.3390/jpm12081323
- 3 22. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of
- 4 risk variants and genes for coronary artery disease in over a million participants. Nat
- 5 Genet 2022;54:1803-1815. doi: 10.1038/s41588-022-01233-6
- 6 23. All of Us All of Us Genomic Quality Report
- 7 https://support.researchallofus.org/hc/en-us/articles/4617899955092-All-of-Us-
- 8 <u>Genomic-Quality-Report-</u>
- 9 24. Yu S, Ma Y, Gronsbell J, et al. Enabling phenotypic big data with PheNorm. J Am
- 10 *Med Inform Assoc* 2018;**25**:54-60. doi: 10.1093/jamia/ocx111
- 11 25. Castro VM, Gainer V, Wattanasin N, et al. The Mass General Brigham Biobank
- 12 Portal: an i2b2-based data repository linking disparate and high-dimensional patient
- data to support multimodal analytics. *J Am Med Inform Assoc* 2022;**29**:643-651. doi:
- 14 10.1093/jamia/ocab264
- 15 26. Patel AP, Wang M, Ruan Y, et al. A multi-ancestry polygenic risk score improves
- risk prediction for coronary artery disease. *Nat Med* 2023;**29**:1793-1803. doi:
- 17 10.1038/s41591-023-02429-x
- 18 27. Ruan Y, Lin YF, Feng YA, et al. Improving polygenic prediction in ancestrally
- diverse populations. *Nat Genet* 2022;**54**:573-580. doi: 10.1038/s41588-022-01054-7
- 20 28. Patel AP, Khera AV. Advances and Applications of Polygenic Scores for
- 21 Coronary Artery Disease. Annu Rev Med 2023;74:141-154. doi: 10.1146/annurev-med-
- 22 042921-112629

1	29.	Prive F, Arbel J, Vilhjalmsson BJ. LDpred2: better, faster, stronger.			
2	Bioinformatics 2021;36:5424-5431. doi: 10.1093/bioinformatics/btaa1029				
3	30.	Lambert SA, Gil L, Jupp S, et al. The Polygenic Score Catalog as an open			
4	datab	ase for reproducibility and systematic evaluation. Nat Genet 2021;53:420-425. doi:			
5	10.10	38/s41588-021-00783-5			
6	31.	Matsushita K, Sang Y, Ning H, et al. Lifetime Risk of Lower-Extremity Peripheral			
7	Artery	Disease Defined by Ankle-Brachial Index in the United States. J Am Heart Assoc			
8	2019;	8:e012177. doi: 10.1161/JAHA.119.012177			
9	32.	Fahed AC, Wang M, Patel AP, et al. Association of the Interaction Between			
10	Famil	ial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk			
11	of Co	ronary Artery Disease. JAMA Netw Open 2022; 5 :e222687. doi:			
12	10.10	01/jamanetworkopen.2022.2687			
13	33.	Klarin D, Tsao PS, Damrauer SM. Genetic Determinants of Peripheral Artery			
14	Disea	ase. <i>Circ Res</i> 2021; 128 :1805-1817. doi: 10.1161/CIRCRESAHA.121.318327			
15	34.	van Zuydam NR, Stiby A, Abdalla M, et al. Genome-Wide Association Study of			
16	Perip	heral Artery Disease. Circ Genom Precis Med 2021; 14 :e002862. doi:			
17	10.11	61/CIRCGEN.119.002862			
18	35.	Criqui MH, Matsushita K, Aboyans V, et al. Lower Extremity Peripheral Artery			
19	Disea	se: Contemporary Epidemiology, Management Gaps, and Future Directions: A			
20	Scien	tific Statement From the American Heart Association. Circulation 2021; 144 :e171-			
21	e191.	doi: 10.1161/CIR.000000000000000000000000000000000000			

1	36. van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR. Gene	etic correlations
2	of polygenic disease traits: from theory to practice. Nat Rev Genet 2019	; 20 :567-581.
3	doi: 10.1038/s41576-019-0137-z	
4	37. Truong B, Hull LE, Ruan Y, et al. Integrative polygenic risk score	improves the
5	prediction accuracy of complex traits and diseases. Cell Genom 2024;4	:100523. doi:
6	10.1016/j.xgen.2024.100523	
7	38. Natarajan P, Young R, Stitziel NO, et al. Polygenic Risk Score Id	entifies
8	Subgroup With Higher Burden of Atherosclerosis and Greater Relative I	3enefit From
9	Statin Therapy in the Primary Prevention Setting. Circulation 2017;135:2	2091-2101. doi:
10	10.1161/CIRCULATIONAHA.116.024436	
11	39. Anand SS, Caron F, Eikelboom JW, et al. Major Adverse Limb Ev	vents and
12	Mortality in Patients With Peripheral Artery Disease: The COMPASS Tri	al. <i>J Am Coll</i>
13	<i>Cardiol</i> 2018; 71 :2306-2315. doi: 10.1016/j.jacc.2018.03.008	
14	40. Kullo IJ, Jouni H, Austin EE, et al. Incorporating a Genetic Risk S	core Into
15	Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipopro	tein Cholesterol
16	Levels (the MI-GENES Clinical Trial). Circulation 2016; 133 :1181-1188.	doi:
17	10.1161/CIRCULATIONAHA.115.020109	
18	41. Muse ED, Chen SF, Liu S, et al. Impact of polygenic risk commu	nication: an
19	observational mobile application-based coronary artery disease study.	VPJ Digit Med
20	2022; 5 :30. doi: 10.1038/s41746-022-00578-w	
21	42. Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to	a Healthy
22	Lifestyle, and Coronary Disease. N Engl J Med 2016; 375 :2349-2358. do	oi:

23 10.1056/NEJMoa1605086

1 Legends

2 Figure 1. Schematic of GPS_{PAD} construction and study design.

- 3 1A. Overview of GPS_{PAD} development using GWAS summary statistics for PAD and 14
- 4 related traits stratified by African, East Asian, European, Latino, or South Asian
- 5 ancestry.
- 6 1B. GPS_{PAD} was then evaluated in three validation datasets consisting of distinct,
- 7 ancestrally diverse individuals, with outcomes including PAD (prevalent and incident),
- 8 ankle-brachial indices, and MALE. Diagram designed with FreePik. AFR, African. EAS,
- 9 East Asian. EUR, European. LAT, Latino. LD_{ref}, ancestry-matched LD reference panel.
- 10 MENA, Middle Eastern/North African. SAS, South Asian.
- 11

12 Figure 2: GPS_{PAD} is an integrated polygenic score that stratifies PAD risk in

13 diverse ancestries

- 14 2A. Prevalence of PAD across GPS_{PAD} percentiles in the UK Biobank validation dataset
- 15 (N = 304,294).
- 16 2B. Estimated PAD risk in the top and bottom of GPS_{PAD} percentile distributions relative
- 17 to the middle quintile (40-59%), as assessed in logistic regression models adjusted for
- age, sex, genotyping array, and ten principal components of ancestry. Results are
- 19 shown on log-axis.
- 20 2C. Risk of PAD associated with GPS_{PAD} in ancestral subgroups in the UK Biobank.
- 21 Results were calculated from a logistic regression model with age, sex, genotyping

22 array, and ten principal components as covariates.

1 Figure 3. GPS_{PAD} shows improved transferability to external cohorts.

- 2 4A. OR per-SD change of polygenic scores in external validation cohorts, AoU (N =
- 3 237,173) and MGBB (N = 37,017).
- 4 4B. Predictive performance for each score is also shown in ancestry subgroups: African
- 5 individuals in AoU (N = 51,691) and MGBB (N = 1,945); East Asians in AoU (N = 5,268),
- 6 European individuals in AoU (N = 119,167) and MGBB (N = 32,139); Latino individuals
- 7 in AoU (N = 39,576) and MGBB (N = 2,933); and South Asian individuals in AoU (N =
- 8 2,289).
- 9 OR were calculated from a logistic regression model adjusted for age, sex, genotyping
- 10 array, and the first ten principal components. Asterisks represent P-value for
- 11 associations, *=P<0.05. **=P<0.01. ***P<0.0001.
- 12 EAS, East Asian. EUR, European. LAT, Latino. SAS, South Asian.
- 13

14 Figure 4. Performance of GPS_{PAD} in predicting incident PAD in the UK Biobank.

15 4A. Changes in C-statistic of GPS_{PAD} (red point) and clinical risk factors (blue points)

16 relative to the baseline model including age, sex, and the first ten principal components

17 of ancestry (gray point), as calculated from Cox proportional hazards models in the UK

- 18 Biobank holdout validation dataset. Lines represent confidence intervals of the C-
- 19 statistic change.
- 4B-C. 10-year rates of PAD according to lifestyle and genetic categories, showing the
- 21 influence of smoking (4B) and dietary patterns (4C). Shown are standardized
- 22 cumulative rates of incident PAD standardized to the population averages for each
- 23 covariate in the Cox models.

2	Figure 5. Incorporation of GPSPAD into screening criteria and PAD diagnosis.
3	5A. 10-year incidence of first-occurring PAD events from prospective analyses of
4	individuals without prior PAD in the UK Biobank. Cox proportional hazards regression
5	models were used to calculate the 10-year event risk among groups for which current
6	clinical guidelines recommend ABI screening ⁸ (blue) and individuals in the top 5%
7	GPS_{PAD} with individual risk factors (red). Error bars represent 95% CI and are not
8	completely shown for groups in the age<50y with diabetes + CKD or top 5% $\mbox{GPS}_{\mbox{PAD}}$ +
9	CKD, but can be found in Supplemental Table 16.
10	5B. Loess regression plot of GPS_{PAD} and minimum ABI among a subset of individuals in
11	the Mass General Brigham Biobank (N = 763).
12	5C. Mean ABI for individuals in the top percentiles of $GPS_{PAD.}$ * indicates percentile
13	group with mean ABI <u><</u> 0.9.
14	AAA, abdominal aortic aneurysm. CKD, chronic kidney disease.
15	
16	Figure 6. GPS _{PAD} stratifies risk for incident major adverse limb events among
17	individuals with PAD.
18	6A. Kaplan-Meier curves of MALE according to high GPS_{PAD} compared to the remainder
19	of the PAD population, standardized to the mean age and sex of each cohort.
20	6B. Risk associated with polygenic scores for incident MALE among individuals with
21	diagnosed PAD in the UK Biobank (N = 2,094), Mass General Brigham Biobank (N =
22	867), and All of Us (N = 8,022). HRs were calculated from adjusted Cox regression

- models including age, sex, genotyping array, the first ten principal components of
- ancestry as covariates.



Validate PAD prediction performance in 3 distinct populations

<u>UK Biobank</u>		Mass General Brigham	All of	<u>f Us</u>
6,939 AFR	1,335 MENA	1,945 AFR	51,691 AFR	39,576 LAT
1,761 EAS	7,680 SAS	32,139 EUR	5,268 EAS	509 MENA
286,356 EUR	1	2,933 LAT	119,167 EUR	2,289 SAS

Assess utility of GPS_{PAD} in guiding screening and secondary prevention



- Assess magnitude of risk discrimination ability for incident PAD
 - Evaluate relationship of GPS_{PAD} with ankle-branchial indices
 - Test association of $\text{GPS}_{_{\text{PAD}}}$ with incident MALE in prevalent PAD



50

GPS_{PAD} percentile (%)

4

2

0

0

25

0.78



Bottom 5% Bottom 20% Top 10% Top 1% GPS_{PAD} percentile group

С	Subgroup	N PAD (%)	OR (95% CI)	P-value	
	Ancestry				
	African	126/6,939 (1.8%)	1.26 (1.01-1.59)	0.048	
	European	6,205/286,356 (2.2%)	1.66 (1.62-1.71)	<0.0001	•
	East Asian	20/1,761 (1.1%)	1.60 (1.01-2.53)	0.045	
	Middle Eastern/ North African	30/1,558 (1.9%)	1.64 (1.10-2.44)	0.015	
	South Asian	183/7,680 (2.4%)	1.25 (1.07-1.46)	0.004	

100

medRxiv preprint doi: https://doi.org/10.1101/2024.10.04.24314847; this version posted October 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 3 It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2024.10.04.24314847; this version posted October 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The day of the da

Figure 4







